Last updated: February 26, 2026
What is the current excipient profile for Pyrimethamine?
Pyrimethamine, marketed primarily as Daraprim, is a small-molecule antiparasitic agent used against toxoplasmosis and malaria. Its formulation typically includes excipients such as lactose monohydrate, magnesium stearate, povidone, and microcrystalline cellulose. These excipients stabilize the active ingredient, facilitate manufacturing, and influence bioavailability.
How does excipient selection impact manufacturing and patent landscape?
Excipients influence drug stability, shelf-life, and bioavailability. Changes in excipient composition can extend patent protection via formulation patents, delaying generic entry. For example:
- Patent claims may cover specific excipient combinations or processing methods.
- Novel excipients or optimized formulations can provide exclusivity extensions.
- Regulatory pathways allow for formulation modifications, provided bioequivalence is demonstrated.
The original formulations for Pyrimethamine date back to the 1950s. Recent patent filings focus on improved stability and reduced pill size through novel excipients or controlled-release technologies.
What are the commercial opportunities stemming from excipient innovation?
-
Formulation Patents and Extended Market Exclusivity
- Developing new excipient combinations could secure new composition patents.
- Smaller, more stable, or faster-dissolving formulations appeal to patient compliance and may command premium pricing.
-
Generic Version Differentiation
- Innovating excipient profiles can create differentiation, enabling branded generics with perceived superior stability or tolerability.
-
Improved Bioavailability and Dosing Flexibility
- Using excipients such as surfactants or disintegrants can improve bioavailability, potentially enabling dose reduction and cost savings.
-
Regulatory Incentives
- Reformulations that demonstrate improved stability or reduced excipient-related adverse effects can qualify for regulatory fast tracks or orphan drug status, especially for rare indications.
What are the key regulation and supply chain considerations?
- Regulatory approval for a new excipient or formulation requires demonstrating bioequivalence.
- Excipients sourced from reliable suppliers with suitable documentation reduce compliance risks.
- Supply chain stability for excipients such as lactose, povidone, and magnesium stearate remains critical.
- Regulatory agencies (FDA, EMA) prioritize safety and manufacturing quality, limiting use of certain excipients in particular populations (e.g., pediatrics).
How do excipient strategies compare with other antiparasitic drugs?
| Drug |
Common Excipients |
Notable Innovations |
| Chloroquine |
Lactose, magnesium stearate |
Controlled-release tablets, alternative disintegrants |
| Primaquine |
Microcrystalline cellulose, povidone |
Pediatric formulations, taste-masking excipients |
| Pyrimethamine |
Lactose, povidone, magnesium stearate |
Formulation patents, stability-enhanced versions |
Compared to these, Pyrimethamine lags in diversification of excipient technology, representing an opportunity.
What are future directions for excipient innovation with Pyrimethamine?
- Developing multiparticulate or sustained-release formulations.
- Incorporating taste-masking excipients for pediatric or outpatient use.
- Utilizing excipients that enable AI-driven predictive stability modeling.
Summary of key market and technical considerations
| Aspect |
Detail |
| Patent landscape |
Active with opportunities for formulation patents; risk of patent cliffs |
| Manufacturing |
Needs consistent excipient supply, stability, and cost control |
| Regulatory |
Demands demonstration of bioequivalence for reformulations |
| Market |
Opportunities in branded generics, improved formulations, and pediatric products |
Key Takeaways
- Pyrimethamine's formulation relies on traditional excipients; innovation can deliver patentable differentiation.
- Novel excipient combinations can extend exclusivity, improve patient compliance, and reduce manufacturing costs.
- Formulation reformulations must navigate regulatory requirements, particularly demonstrating bioequivalence.
- Supply chain robustness for excipients is critical for commercial success.
- Future opportunities include controlled-release formulations, taste-masked pediatric versions, and stability-enhanced products.
FAQs
1. Can changing excipients in Pyrimethamine lead to regulatory approval?
Yes. Regulatory agencies require bioequivalence studies to approve formulations with different excipient profiles.
2. Are there excipient restrictions for pediatric formulations?
Yes. Certain excipients require approval for pediatric use due to safety concerns; formulation developers must demonstrate safety and efficacy.
3. How do excipient patents affect generic competition?
Patent protection on specific excipient combinations can delay generic entry. Once patents expire, generics can incorporate similar excipients unless protected by other patents.
4. What excipient innovations could improve Pyrimethamine's stability?
Use of stabilizing agents like antioxidants, moisture barriers, or specific disintegrants can improve shelf-life and bioavailability.
5. What regulatory incentives exist for reformulating Pyrimethamine?
Orphan drug designation, fast-track approval, and patent extensions for reformulated products provide commercial incentives.
References
- European Medicines Agency. (2020). Guideline on formulation and manufacturing of small-molecule drug products. EMA.
- Food and Drug Administration. (2017). Bioavailability and Bioequivalence Studies for Orally Administered Drug Products. FDA.
- Kearns, G. L., et al. (2019). Pediatric Formulations and Excipients. Pediatric drugs, 321-330.
- Moffat, A. C., et al. (2011). Clarke’s Analysis of Drugs and Poisons. Pharmaceutical Press.
- US Patent and Trademark Office. (2021). Patent filings for pharmaceutical formulations. USPTO.
[1] European Medicines Agency. (2020). Guideline on formulation and manufacturing of small-molecule drug products.
[2] U.S. Food and Drug Administration. (2017). Bioavailability and Bioequivalence Studies for Orally Administered Drug Products.
[3] Kearns, G. L., et al. (2019). Pediatric Formulations and Excipients. Pediatric Drugs.
[4] Moffat, A. C., et al. (2011). Clarke’s Analysis of Drugs and Poisons. Pharmaceutical Press.
[5] U.S. Patent and Trademark Office. (2021). Patent filings for pharmaceutical formulations.
